Combretastatin A-4

A synthetic Combretum caffrum-derived cell-permeable stilbenoid phenol that competes with colchicine (Cat No. 234115) tubulin binding (by 96.4% at equal molar concentration; Ki = 1.1 µM) and interferes with tubulin polymerization (IC₅₀ = 2-3 µM) as well as cellular microtubule assembly. In addition to its antimitotic and in vitro cancer growth inhibition activity (IC₅₀ = 7 nM in L1210 cultures), CA4 also acts as an antivascular agent and effectively induces tumor cell necrosis in vivo by targeting endothelial cytoskeleton.

A synthetic Combretum caffrum-derived cell-permeable stilbenoid phenol that competes with colchicine (Cat. No. 234115) tubulin binding (by 96.4% at equal molar concentration; Ki = 1.1 µM) and interferes with tubulin polymerization (IC₅₀ = 2-3 µM) as well as cellular microtubule assembly. In addition to its antimitotic and in vitro cancer growth inhibition activity (IC₅₀ = 7 nM in L1210 cultures), CA4 also acts as an antivascular agent and effectively induces tumor cell necrosis in vivo by targeting endothelial cytoskeleton.

Packaged under inert gas

Toxicity: Standard Handling (A)

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Tron, G.C., et al. 2006. J. Med. Chem.49, 3033.
Griggs, J., et al. 2001. Lancet Oncol.2, 82.
Pettit, G.R., et al. 1989. Experientia45, 209.
Lin, C.M., et al. 1988. Mol. Pharmacol.34, 200.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany